Intra-Cellular Therapies (NASDAQ:ITCI) reported its Q4 earnings results on Tuesday, March 1, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
Earnings
Intra-Cellular Therapies missed estimated earnings by 5.0%, reporting an EPS of $-1.05 versus an estimate of $-1.0.
Revenue was up $13.22 million from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.03 which was followed by a 2.93% drop in the share price the next day.
Here's a look at Intra-Cellular Therapies's past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | -0.92 | -0.80 | -0.80 | -0.85 |
| EPS Actual | -0.95 | -0.85 | -0.65 | -0.76 |
| Revenue Estimate | 22.12M | 19.44M | 16.50M | 11.84M |
| Revenue Actual | 22.21M | 20.05M | 15.88M | 12.45M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
